Archives
-
Corin Triggers Cuproptosis in Liver Cancer
2026-08-30
The reference study identifies Corin as a dual KDM1A/HDAC1 inhibitor that suppresses hepatocellular carcinoma cell growth and links this activity to FDX1-associated cuproptosis. Its screening-to-mechanism workflow illustrates how a CCK-8-based phenotypic assay can help prioritize epigenetic compounds for mechanistic cancer research, while also highlighting the need for validation beyond a limited cell-line panel.
-
H-Aggregated NIR-II Fluorophore for Cancer Therapy
2026-08-29
Yu et al. developed an RR9-functionalized liposome that transfers H-aggregated IR-1061 from the carrier to tumor cell membranes, combining NIR-II fluorescence imaging with more persistent photothermal therapy. Loading carboplatin added temperature-sensitive chemotherapy, producing a lipid nanosystem for image-guided thermochemotherapy while highlighting membrane-state engineering as a design strategy.
-
JNJ-10198409: PDGF Receptor Inhibitor
2026-08-28
JNJ-10198409 is a nanomolar platelet-derived growth factor receptor inhibitor for dissecting PDGF-BB-driven proliferation, tumor–stroma signaling, and angiogenesis-associated phenotypes. This guide turns its ATP-competitive mechanism and practical solubility profile into staged, quantitative workflows with controls for pathway specificity and assay robustness.
-
Engineering mRNA That Performs: From Tail to Therapy
2026-08-28
Polyadenylation is more than a finishing step in mRNA engineering: it is a controllable design variable that can influence RNA persistence, translation, and experimental reproducibility. This thought-leadership analysis connects the HyperScribe™ Poly (A) Tailing Kit with findings from NGFR100W mRNA delivery research and outlines a practical path from in vitro transcription RNA modification to translational validation.
-
Enhanced ECL Detection for BMSC Protein Studies
2026-08-27
Discover how the ECL Chemiluminescent Substrate Detection Kit supports sensitive, reproducible protein immunodetection in BMSC toxicology studies. This article connects pathway-focused western blot design with practical decisions for phosphoprotein measurement, imaging, and assay validation.
-
Z-YVAD-FMK in Caspase-1 Pyroptosis Assays
2026-08-27
Use Z-YVAD-FMK to distinguish caspase-1-dependent pyroptosis from apoptosis, inflammasome-associated signaling, and unrelated forms of cell death. This workflow combines dose-controlled inhibition with GSDMD, cytokine, viability, and caspase-3 readouts for stronger cancer research conclusions.
-
Nitric Oxide Nanomotors for Glioblastoma Immunotherapy
2026-08-26
The reference study develops a chemotactic nanomotor that uses the reactive glioblastoma microenvironment to improve brain-tumor localization and coordinate antitumor immune responses. Its angiopep-2 and mitochondria-targeted lonidamine design links blood–brain barrier transport, tumor-cell killing, immunogenic cell death, and immune memory in one delivery strategy.
-
LNP–mRNA Delivery in Pregnancy: Structure and Route
2026-08-26
This PNAS study shows that lipid nanoparticle composition and administration route jointly determine mRNA expression, inflammation, and maternal–fetal outcomes in pregnant mice. Its mechanistic findings provide a framework for separating delivery potency from immunological risk when designing pregnancy-relevant RNA therapies and reporter workflows.
-
PDHA1 Succinylation and α-KGA in Cholangiocarcinoma
2026-08-25
A 2025 Nature Communications study identifies a PDHA1 K83 succinylation–α-KGA–OXGR1 signaling axis that connects cholangiocarcinoma metabolism with impaired macrophage antigen presentation. The findings provide a mechanistic explanation for immune escape and suggest that targeting this metabolic post-translational modification may improve gemcitabine–cisplatin responses in preclinical models.
-
Standardized Whole-Blood Stimulation in Immunometabolism
2026-08-25
Zhao and colleagues present a standardized whole-blood stimulation protocol for testing how metabolic interventions reshape human immune responses. By combining pathogen-associated stimuli, pathway-directed inhibitors, and cytokine measurement, the workflow distinguishes stimulus- and cytokine-specific metabolic effects while preserving the complexity of whole blood.
-
v-Agatoxin-IVA and Low-Affinity N-Type Ca²⁺ Blockade
2026-08-24
Sidach and Mintz showed that v-Agatoxin-IVA is not exclusively a high-affinity P-type calcium channel blocker: at micromolar exposure, it also inhibits N-type and Q-like currents in mammalian neurons. The study provides a cautionary framework for interpreting toxin-based channel classification and for separating high-affinity subtype selectivity from low-affinity, voltage-dependent effects.
-
WAY-100635 in 5-HT1A Pain Circuit Assays
2026-08-24
Use WAY-100635 to convert associations between serotonergic signaling, pain, and affect into testable 5-HT1A receptor hypotheses. This workflow combines receptor binding, functional antagonism, behavioral pharmacology, and circuit-level readouts while clearly separating evidence from the 2026 cannabidiol study from new causal experiments.
-
ATP as a Translational Signal in Cancer Immunity
2026-08-23
ATP is more than a metabolic endpoint: in immunogenic cell death, it can function as an extracellular alarm signal. This article connects foretinib-driven immune remodeling in colorectal cancer with practical assay design, showing how luminescent ATP quantification can strengthen mechanistic and translational decisions without overinterpreting a single readout.
-
Recombinant Annexin V on Endothelial Thrombin Formation
2026-08-22
The 1994 reference study established that recombinant annexin V binds directly to endothelial-cell surfaces and inhibits thrombin generation by masking procoagulant phospholipid sites. Its quantitative binding and inhibition data clarify how a phosphatidylserine binding protein can regulate coagulation on a cellular surface rather than only on artificial lipid vesicles.
-
pH-Sensitive cRGD-PEG-siRNA for Glioblastoma
2026-08-22
The 2024 Bioconjugate Chemistry study developed a pH-responsive cRGD-PEG-siEGFR conjugate intended to improve glioblastoma targeting while reducing renal accumulation and extending circulation. Its combined molecular characterization, cell-based testing, and in vivo biodistribution data support a delivery strategy that links αvβ3 recognition, acid-sensitive PEG behavior, and EGFR silencing.